Company intelligence / Profile preview

FlexGen

Ownership: Private
Development stage: Other

Overview

FlexGen is a Dutch biotech company specializing in custom microarray synthesis instruments and target enrichment kits used in genomics research, sequencing, and diagnostic applications. Its FleXelect product line includes whole-exome enrichment kits, cancer risk panels, hereditary disease panels, and BRCA screening solutions. The company's technologies are used by leading academic centers such as Leiden University Medical Center and BGI for large-scale genomics projects like Genome of the Netherlands. FlexGen is backed by investors including Omnes Capital and BioGeneration Ventures.

Therapeutic areas: Rare DiseasesOncologyOther
Modalities: Microarray-based genetic analysisTarget enrichment kitsDeviceDiagnostic device
Industry: Molecular Diagnostics

Partnerships

BGILeiden University Medical Center

Beyond the preview

Go deeper on FlexGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FlexGen.

Explore the full profile